AstraZeneca has sold its stake in Moderna for more than $1 billion: The Times

Global Economy

Reuters
01 March, 2021, 09:00 am
Last modified: 01 March, 2021, 09:13 am
AstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University Covid-19 vaccine on a commercial basis in future if the virus becomes endemic
The AstraZeneca logo is pictured outside the AstraZeneca office building in Brussels as part of the coronavirus disease (COVID-19) vaccination campaign, Belgium, January 28, 2021. REUTERS/Johanna Geron

AstraZeneca Plc has sold its 7.7% stake in Moderna Inc for more than $1 billion after the US biotechnology company's shares soared on the back of its coronavirus vaccine breakthrough, The Times reported.

The report added that it was not clear over what period British-based AstraZeneca sold its holding in Moderna.

AstraZeneca and Moderna did not immediately respond to requests for comment.

AstraZeneca is retaining partnership with Moderna on other disease treatments and could sell its AstraZeneca/Oxford University Covid-19 vaccine on a commercial basis in future if the virus becomes endemic, the report added.

Moderna, whose vaccine is cleared for emergency use against Covid-19 in the United States, said last week it was expecting sales of $18.4 billion from its coronavirus vaccine this year.

Related Topics

Coronavirus chronicle / Top News / World+Biz

AstraZeneca Covid-19 Vaccine / AstraZeneca vaccine / AstraZeneca Plc / British Drug Maker AstraZeneca Plc / Moderna Inc / Moderna Covid-19 Vaccine / Moderna Vaccine

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.